ArticleInternational journal of molecular sciences2023
A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Data-driven endocrine-metabolic phenotypes in young women with polycystic ovary syndrome and associations with cardiometabolic risk markers.Journal of endocrinological investigation · 2026Article
- Expression of Hypoxia-Inducible Factor 1a (HIF-1a), Regulatory T Cells (Treg) and T Helper 17 Cells (Th17) in PCOS Phenotype D Patients from Polish Population.International journal of molecular sciences · 2026Article
- Serum Chemerin Levels in Polish Women with PCOS-Phenotype D.Journal of clinical medicine · 2026Article
- FromFrontiers in endocrinology · 2026Review
- From Ovarian to Endocrine-Metabolic Roots: Aligning PCOS Nomenclature with Pathophysiology.Journal of obstetrics and gynaecology of India · 2025Article
- Article
- Impact of Polycystic Ovary Syndrome Hyperandrogenic Phenotypes A and Non-Hyperandrogenic D on Pregnancy Outcomes After in vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI).International journal of women's health · 2025Article
- Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO).Frontiers in cardiovascular medicine · 2025Review
- PCOS and Inositols - Advances and Lessons We are Learning. A Narrative Review.Drug design, development and therapy · 2025Review
- Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2024Review
- Hyperandrogenic eumenorrheic NON-PCOS womenJournal of clinical & translational endocrinology · 2024Article
- PCOS phenotype focus: phenotype D under the magnifying glass.Archives of gynecology and obstetrics · 2024Review
- Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study.Journal of ovarian research · 2024Article
- The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.Gynecologic and obstetric investigation · 2024Article
- Article
- Diet Plus Inositols, α-Lactalbumin andNutrients · 2023Article
- Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes.Biomedicines · 2023Article
- D-Chiro-Inositol in Endometrial Hyperplasia: A Pilot Study.International journal of molecular sciences · 2023Article
- Androgen excess: a hallmark of polycystic ovary syndrome.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent evaluation of the published data regarding the PCOS topic has highlighted a paradox in the definition of this condition. Even though the name of the syndrome refers to ovarian dysfunction, it seems that patients diagnosed with PCOS are more likely affected by an endocrine and metabolic issue. The term PCOS might not be appropriate to indicate the phenotypes described by the Rotterdam criteria, since the only phenotype with a gynecological issue alone is PCOS phenotype D. This novel perspective regarding how PCOS is currently defined leads the way to a reinterpretation of the entire pathological context and the treatment prescribed, such as inositols. A new point of view on the etiopathogenesis of the disease completely changes the current meaning of PCOS and consequently the therapeutic rationale evaluated to date.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.